These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

599 related items for PubMed ID: 18042642

  • 21. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis.
    Sokka T, Pincus T.
    Arthritis Rheum; 2003 Feb; 48(2):313-8. PubMed ID: 12571838
    [Abstract] [Full Text] [Related]

  • 22. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders.
    Buch MH, Bingham SJ, Bryer D, Emery P.
    Rheumatology (Oxford); 2007 Jul; 46(7):1153-6. PubMed ID: 17478470
    [Abstract] [Full Text] [Related]

  • 23. Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate.
    Parker A, Izmailova ES, Narang J, Badola S, Le T, Roubenoff R, Ginsburg GS, Maier A, Coblyn JS, Shadick NA, Weinblatt ME.
    J Rheumatol; 2007 Sep; 34(9):1817-22. PubMed ID: 17696278
    [Abstract] [Full Text] [Related]

  • 24. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study.
    Goedkoop AY, Kraan MC, Picavet DI, de Rie MA, Teunissen MB, Bos JD, Tak PP.
    Arthritis Res Ther; 2004 Sep; 6(4):R326-34. PubMed ID: 15225368
    [Abstract] [Full Text] [Related]

  • 25. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T.
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [Abstract] [Full Text] [Related]

  • 26. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
    Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, Klareskog L, Ulfgren AK.
    Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
    [Abstract] [Full Text] [Related]

  • 27. DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment.
    Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, Veys EM, Mielants H, De Clerck L, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Keyser F.
    Arthritis Res Ther; 2005 Jan; 7(5):R1063-71. PubMed ID: 16207323
    [Abstract] [Full Text] [Related]

  • 28. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
    Doyle MK, Rahman MU, Han C, Han J, Giles J, Bingham CO, Bathon J.
    Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645
    [Abstract] [Full Text] [Related]

  • 29. Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis.
    Odai T, Matsunawa M, Takahashi R, Wakabayashi K, Isozaki T, Yajima N, Miwa Y, Kasama T.
    J Rheumatol; 2009 Jun; 36(6):1158-65. PubMed ID: 19369458
    [Abstract] [Full Text] [Related]

  • 30. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC, Chung SJ, Park YB, Lee SK.
    Scand J Rheumatol; 2008 Jun; 37(3):173-8. PubMed ID: 18465450
    [Abstract] [Full Text] [Related]

  • 31. Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor.
    Ernestam S, af Klint E, Catrina AI, Sundberg E, Engström M, Klareskog L, Ulfgren AK.
    Arthritis Res Ther; 2006 Jun; 8(1):R18. PubMed ID: 16507118
    [Abstract] [Full Text] [Related]

  • 32. Differential gene expression profiles may differentiate responder and nonresponder patients with rheumatoid arthritis for methotrexate (MTX) monotherapy and MTX plus tumor necrosis factor inhibitor combined therapy.
    Oliveira RD, Fontana V, Junta CM, Marques MM, Macedo C, Rassi DM, Passos GA, Donadi EA, Louzada-Junior P.
    J Rheumatol; 2012 Aug; 39(8):1524-32. PubMed ID: 22753658
    [Abstract] [Full Text] [Related]

  • 33. Effects of intra-articular corticosteroids and anti-TNF therapy on neutrophil activation in rheumatoid arthritis.
    Wittkowski H, Foell D, af Klint E, De Rycke L, De Keyser F, Frosch M, Ulfgren AK, Roth J.
    Ann Rheum Dis; 2007 Aug; 66(8):1020-5. PubMed ID: 17223658
    [Abstract] [Full Text] [Related]

  • 34. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity.
    Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, Mielants H, De Clerck L, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Keyser F.
    Arthritis Res Ther; 2006 Aug; 8(4):R112. PubMed ID: 16978395
    [Abstract] [Full Text] [Related]

  • 35. Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis.
    Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y.
    Ann Rheum Dis; 2008 Mar; 67(3):380-8. PubMed ID: 17660216
    [Abstract] [Full Text] [Related]

  • 36. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.
    Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, Tak PP.
    Arthritis Rheum; 2007 Mar; 56(3):772-8. PubMed ID: 17328049
    [Abstract] [Full Text] [Related]

  • 37. Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks.
    Lisbona MP, Maymo J, Perich J, Almirall M, Pérez-García C, Carbonell J.
    J Rheumatol; 2008 Mar; 35(3):394-7. PubMed ID: 18203329
    [Abstract] [Full Text] [Related]

  • 38. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A, Pontikaki I, Teruzzi B, Desiati F, Gerloni V, Gattinara M, Cimaz R, Fantini F.
    Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
    [Abstract] [Full Text] [Related]

  • 39. Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis.
    Fabris M, Tolusso B, Di Poi E, Assaloni R, Sinigaglia L, Ferraccioli G.
    J Rheumatol; 2002 Sep; 29(9):1847-50. PubMed ID: 12233877
    [Abstract] [Full Text] [Related]

  • 40. Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies.
    Kievit W, Fransen J, Adang EM, Kuper HH, Jansen TL, De Gendt CM, De Rooij DJ, Brus HL, van de Laar MA, Van Riel PC.
    Ann Rheum Dis; 2009 Jun; 68(6):844-9. PubMed ID: 18625616
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.